Clinical trials: Empagliflozin
Nephrotic Syndrome
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome.
- Trial name
- SGLT2-NS (NCT07214818)
- Testing
- Dapagliflozin, Empagliflozin, Standard Therapy
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Mansoura University
Healthy
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin, linagliptin \& metformin extended release (XR) and the single tablets…
- Trial name
- NCT02821910
- Testing
- High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed, 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR, High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Decompensated Heart Failure
Add-on Diuretics in Acute Decompensated Heart Failure
The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.
- Trial name
- NCT07372040
- Testing
- empagliflozin, Acetazolamide, metolazone
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Tanta University
Type 2 Diabetes Mellitus (T2DM), Cognitive Dysfunction
SGLT2 Inhibitors and Cognitive Function in Adults With Type 2 Diabetes (SaveMinD)
This study is a prospective, randomized, open-label trial with blinded outcome assessment (PROBE design) designed to evaluate the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy on cognitive function in adults…
- Trial name
- SaveMinD (NCT07694596)
- Testing
- SGLT2 Inhibitor, Standard Diabetes Care
- Where
- Slovenia
- Volunteers
- 200 people
- Sponsor
- University of Primorska
Pulmonary Arterial Hypertension
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin.
- Trial name
- NCT06554301
- Testing
- empagliflozin in treatment pulmonary aerterial hypertension
- Where
- China
- Volunteers
- 72 people
- Sponsor
- China National Center for Cardiovascular Diseases
Healthy
Drug Interaction Study of Digoxin and BI 10773
The objective of the study is to investigate the relative bioavailability of digoxin after concomitant multiple oral administration of BI 10773 and a single dose of digoxin in comparison to digoxin given alone to healthy male and…
- Trial name
- NCT01306175
- Testing
- Digoxin plus BI 10773, Digoxin
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heart Failure, Preserved Ejection Fraction
Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction
The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.
- Trial name
- NCT07047508
- Volunteers
- 3,000 people
- Sponsor
- Boehringer Ingelheim
Metabolic Syndrome, Obesity & Overweight
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
We investigate the role of empagliflozin in the treatment of obesity in PLWH.
- Conditions
- Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)
- Trial name
- NCT07336797
- Testing
- Empagliflozin (oral)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Abdelrahman Mahmoud
Kidney Disease, Chronic
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.
- Trial name
- NCT06527846
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 1,024 people
- Sponsor
- Boehringer Ingelheim
Metabolic Syndrome
Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment
The DEMETER - SIRIO 11 study is a phase III, multicenter, randomized, open-labled, investigator-initiated clinical trial with a 6 month follow-up.
- Trial name
- DEMETER (NCT05905965)
- Testing
- Empagliflozin 20 mg, Empagliflozin 10 mg
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet versus Synjardy XR tablets…
- Trial name
- NCT07694115
- Testing
- Empagliflozin / Metformin Extended-Release Tablet, Synjardy XR tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Chronic Hepatitis b, NAFLD
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Chronic hepatitis B (CHB) affects 257million individuals worldwide. In 2017, it caused around 39.7 million cases of cirrhosis and 0.4 million cirrhosis-related deaths in 2017.
- Conditions
- Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver
- Trial name
- NCT05147090
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- The University of Hong Kong
Bipolar Disorder, Bipolar Depression
Empagliflozin Adjunctive Therapy in Bipolar Depression
Bipolar disorder is a long-term mental health condition that causes mood changes, with depressive episodes being the most frequent and disabling.
- Conditions
- Bipolar Disorder, Bipolar Depression, Insulin Resistance
- Trial name
- EMPA-BD (NCT07472920)
- Testing
- Empagliflozin (EMPA)
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo
Non-alcoholic Steatohepatitis, Liver Diseases
Reducing Non-Alcoholic Steatohepatitis
The goal of this clinical trial is to learn if empagliflozin works to treat non-alcoholic steatohepatitis in adults. The objectives are: Primary Objective To evaluate the change in histological grading and staging of NASH in…
- Conditions
- Non-alcoholic Steatohepatitis, Liver Diseases, Diabetes Mellitus, Type 2, Fibrosis, Liver
- Trial name
- RedNASH (NCT06519448)
- Testing
- Empagliflozin 10 miligrams (mg)
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Military University Hospital, Prague
Diabetes Mellitus, Type 2
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients…
- Trial name
- NCT01159600
- Testing
- BI 10773
- Where
- 148 sites in United States, Canada and 10 more
- Volunteers
- 1,504 people
- Sponsor
- Boehringer Ingelheim
SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Syndrome of inappropriate antidiuresis (SIADH) is characterized by an imbalance of antidiuretic vasopressin (AVP) secretion. The impaired AVP regulation leads to water retention and secondary natriuresis and is a common cause for…
- Trial name
- SANDx (NCT03202667)
- Testing
- Empagliflozin 25mg
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- University Hospital, Basel, Switzerland
Type 2 Diabetes
Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
The aim of this study is to perform a comparison of the efficacy and safety of empagliflozin and vildagliptin in patients with Type 2 Diabetes Mellitus open labelled, multi-centric, parallel, randomized control trial In Type 2…
- Trial name
- NCT05359432
- Testing
- Empagliflozin, Vildagliptin
- Where
- Pakistan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Acute Kidney Injury
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
SGLT2i have been shown to reduce risk for mortality, progression of chronic kidney disease, and cardiovascular outcomes in these populations.
- Trial name
- NCT06124924
- Testing
- SGLT2 inhibitor
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Minnesota
Proteinuria, Diabetes (DM)
Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i
Proteinuria is an early marker of diabetic kidney disease and predicts progression to chronic kidney disease and cardiovascular complications.
- Trial name
- NCT07586371
- Testing
- ARBs alone, ARBs in combination of SGLT2i
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Dr Mudassar Saeed Pansota
Diabetes Mellitus, Type 2
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
- Trial name
- BESTMED (NCT05161429)
- Testing
- DPP4, GLP-1 receptor agonist, Basal Insulin
- Where
- 5 sites in United States
- Volunteers
- 550,000 people
- Sponsor
- Brigham and Women's Hospital